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Several ecdysteroid acetonides act as adjuvant chemo-sensitizing agents against various
cancer cell lines, and they can be formulated to self-assembling nanoparticle (NP) pro-drugs
through a hydrolysable conjugation with squalene. In the bloodstream such squalenoylated
nanoparticles dissolve into low-density lipoprotein (LDL) that allows targeting tissues
containing high levels of LDL-receptors. In this work, ajugasterone C 2,3;20,22-diacetonide
(3) and 11a-hydroxypoststerone 2,3-acetonide (4) were squalenoylated to obtain two new
ecdysteroid pro-drugs (6 and 7) and their nano-assemblies (6NP and 7NP). A complete NMR
signal assignment of 6 and 7 was achieved. Interaction of compounds 3 and 4 with
chemotherapeutics was studied by the Chou-Talalay method. Compound 3 showed
strong synergism with doxorubicin on a multi-drug resistant lymphoma cell line. In contrast,
its nanoassembly 6NP significantly decreased the cytotoxicity of doxorubicin on these MDR
cells, strongly suggesting that at least the 2,3-acetonide group was cleaved by the acidic pH
of lysosomes after endocytosis of the prodrug. Further, compound 4 acted in strong
antagonism with paclitaxel on MCF-7 cells and its nanoassemby 7NP also protected MCF-
7 cells from the effect of paclitaxel. Our results suggest that acid-resistant A-ring substitution
would be crucial to design adjuvant antitumor squalenoylated ecdysteroid prodrugs.
Additionally, our results may be considered as a serendipitous discovery of a novel way to
deliver cytoprotective, adaptogen ecdysteroids to healthy tissues with upregulated LDL-R.
Keywords: ecdysteroid, squalene nanoparticle pro-drug, self-assembly, low-density lipoprotein targeting, cancer,
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Nanotechnology offers various perspectives to overcome the
insufficient therapeutic efficacy of a biomolecule. Over the
previous decades, a wide array of nano-sized delivery platforms
had been developed in antitumor chemotherapy for a more
efficient delivery of chemotherapeutic agents to the target
cells (Li et al., 2017). Typically, the use of nanomaterials as in
vivo transport systems serves more than one intention: a) by
placing the drug in a biocompatible, protective matrix, we
can modulate its physicochemical stability in the organism,
therefore improving its pharmacokinetic and pharmacological
properties, and b) by considering the tissue- or cell-specific
delivery mechanism of nanoparticles (NPs) we can have a
partial control over the accumulation and distribution of the
drug, and, accordingly, directly or indirectly target the tumor (Xu
et al., 2015; Shi et al., 2017).
One particularly simple, yet efficient way to design anticancer
NPs is the preparation of self-assembling drug conjugates
(Fumagalli et al., 2016). We can obtain these molecules through
synthesis, by chemically linking the chosen chemotherapeutic agent
to an essential functional unit, the so-called inducer. Organic
molecules, such as terpenes, polysaccharides, or polymeric chains
with high biocompatibility, are widely used as inducers, which can
spontaneously self-assemble into NPs in an aqueous medium
without the need for using any additional surfactants to stabilize
their colloid suspensions (Bildstein et al., 2011; Delplace et al., 2014).
In some instances, connecting the drug and the inducer can be
achieved by using a so-called linker moiety, which may further
enhance the in vivo release of the therapeutic agent from its
conjugate (Borrelli et al., 2014). During the synthetic preparation
of bioconjugates, components are coupled together through
covalent bonds that are hydrolysable in a biological environment
(e.g., esters), so that such self-assembled NPs will typically act as
pro-drugs (Cheetham et al., 2017).
Among the possible inducers, squalene is a particularly
attractive choice due to its biocompatibility, inertness, and the
ease of transforming the terminal double bond to versatile
functional groups that may be linked to the drug (Desmaele
et al., 2012; Maksimenko et al., 2014). It has recently been
revealed that NPs of squalene conjugates do not remain intact
after getting into the bloodstream. Instead, they get dissolved
into lipoproteins (whose most affected fraction depends on the
species, in humans it is mainly low-density lipoprotein or rather
LDL) that will transport them in the bloodstream, and this allows
a unique targeting of cancer cells that commonly display high
expression and activity of LDL receptors (LDL-R) (Sobot
et al., 2017).
Ecdysteroids, analogs of the insect molting hormone ecdysone,
exert a wide range of bioactivities in mammals (Lafont and Dinan,
2003; Dinan et al., 2020). We have previously reported that less
polar ecdysteroid derivatives can strongly sensitize both multi-drug
resistant (MDR) and drug-susceptible cancer cell lines to various
chemotherapeutics (Martins et al., 2012; Martins et al., 2015). We
have been exploring relevant structure-activity relationships over
the years, and found that the most important is the presence of a
2,3-acetonide group (Hunyadi et al., 2017). This moiety isFrontiers in Pharmacology | www.frontiersin.org 2unfortunately also the most chemically sensitive part of these
compounds, particularly in acidic environment. Therefore, nano-
formulation of these compounds can not only serve as a relevant
targeting strategy, but it may also significantly increase their
stability. Previously, we reported the preparation and evaluation
of squalene-conjugates obtained from poststerone 2,3-acetonide 20-
oxime (Bogdan et al., 2018). These compounds, together with 25-
squalenoylated analogs of 20-hydroxyecdysone 2,3;20,22-
diacetonide (20DA), were subsequently formulated into
doxorubicin-containing hetero-nanoparticles that could efficiently
inhibit proliferation of adriamycin-resistant A2780ADR cancer cells
(Fumagalli et al., 2018).
In the present work, we aimed to further expand the available
chemical and pharmacological space by preparing further self-
assembling conjugates and NPs from other, less abundant
ecdysteroids containing an 11a-OH group for a convenient ester
coupling, and to evaluate their effect on the chemoresistance of
MDR and non-MDR cancer cell lines.MATERIALS AND METHODS
Materials
Reagents and solvents were purchased from Sigma (Merck KGaA,
Darmstadt, Germany) and were applied for the corresponding
research purpose without any further purification. Each synthetic
reaction was monitored by thin-layer chromatography (TLC) on
Kieselgel 60F254 silica plates (Merck KGaA, Darmstadt, Germany).
The characteristic spots of materials were examined under UV
illumination at 254 and 366 nm. Ajugasterone C (1) was previously
isolated from Serratula wolffii (Hunyadi et al., 2007).Synthetic Procedures
Synthesis of Compound 2
Compound 2 was prepared according to our previously
published method (Issaadi et al., 2019). Briefly, a 1 g aliquot of
ajugasterone C (1) was dissolved in 80 ml of methanol. One
equivalent of (diacetoxyiodo)benzene (PIDA) was added to the
solution, and subsequently, the reaction mixture was left under
stirring for 45 min at RT. Following this, the solution was
neutralized with 10% aq. NaHCO3 and then, the solvent was
evaporated on a rotary evaporator. The obtained dry residue
was re-dissolved in methanol, and silica gel (~4 g) was added to
the solution. After this, the solvent was removed under reduced
pressure allowing the preparation of the sample for dry loading
flash chromatographic purification. This resulted in the
successful isolation of compound 2 (0.59 g, 74.8%).Synthesis of Compounds 3 and 4
Derivatization of the diols of ecdysteroids 1 and 2 was performed
as published before (Martins et al., 2012). Briefly, a 500 mg
aliquot of the corresponding substrate was dissolved in a
concentration of 1 g/100 ml (50 ml) in acetone. To the
obtained solution, 500 mg of phosphomolybdic acid (PMA)
hydrate was added, and the mixture was sonicated for 25 minSeptember 2020 | Volume 11 | Article 552088
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NaHCO3 and then, the solvent was evaporated under reduced
pressure. The obtained products were extracted from their
aqueous residue using ethyl acetate (3 ml x 100 ml), and the
organic fractions were combined and dried over Na2SO4.
Following this, the drying agent was removed by filtration, and
the solvent was evaporated on a rotary evaporator. The residue
was subjected to flash chromatographic purification to yield
ajugasterone C 2,3;20,22-diacetonide (3; 364 mg, 62.4%), or
11a-hydroxypoststerone 2,3-acetonide (4; 386 mg, 69.8%) in
pure form.
Synthesis of Ecdysteroid Conjugates 6 and 7
Self-assembly inducer squalene was functionalized and
conjugated with sebacic acid following previously published
procedures, which had allowed us the preparation of
compound 5 (Borrelli et al., 2014; Maksimenko et al., 2014).
An aliquot of 0.2 mmol of ecdysteroid 3 (112.2 mg) or 4 (83.7
mg) and 142.7 mg of compound 5 (0.25 mmol, 1.25 equiv.) were
dissolved in 10 ml of dry dichloromethane in a two-neck round-
bottom flask. Later, 48.9 mg of 4-dimethylaminopyridine (DMAP;
0.4 mmol, two equiv.) and 115 mg of (3-dimethylaminopropyl)-N′
-ethylcarbodiimide hydrochloride (EDC·HCl; 0.6 mmol, three
equiv.) were added to the solution, and then, the reaction mixture
was stirred under an argon atmosphere at RT for overnight.
Following this, the solution was neutralized with 10% aq.
NaHCO3 and was diluted with brine (30 ml) allowing to perform
an extraction with dichloromethane (4 ml x 30 ml). The collected
organic fractions were combined and dried under Na2SO4, and
subsequently, the drying agent was removed through filtration. The
solvent of the sample was evaporated, and then, the residue was
purified utilizing preparative NP-HPLC affording the isolation of
compound 6 (180.9 mg, 81.2%) or the side chain-cleaved conjugate
analogue 7 (97.9 mg, 58.9%), as a colorless oil.
Chromatographic Conditions
Following organic synthesis, chromatographic purification of
substances was carried out on either a Combiflash Rf+ flash
chromatographic instrument (TELEDYNE Isco, Lincoln, NE,
USA) equipped with DAD-ELS detection using commercially
available RediSep columns (TELEDYNE Isco, USA), or on
an Armen Spot Prep II preparative HPLC purification system
(Gilson, Middleton, WI, USA) equipped with a dual-wavelength
UV-VIS detector. Flash chromatographic purifications were
performed on 4–24 G silica columns with adequately chosen
eluent ratios of dichloromethane—methanol. For preparative
HPLC separations, a Phenomenex Luna® 5 µm Silica (2) 100
Å 250 mm x 21.2 mm column (Phenomenex Inc., Torrance, CA,
USA) was used, typically in isocratic elution mode with
adequately chosen eluent ratios of cyclohexane—isopropanol.
In general, the applied flow rates were 15 ml/min, and the
wavelengths of detection were 210 andd 250 nm. Purity of the
isolated compounds was determined on a Jasco HPLC
instrument (Jasco International Co. Ltd., Hachioji, Tokyo,
Japan) equipped with LC capillary cables proper for analyticalFrontiers in Pharmacology | www.frontiersin.org 3purposes. The analysis was carried out on a 250 mm x 4.6 mm
analogue of the preparative silica column using the peak area %
data of the PDA chromatogram recorded between 210 and 410
nm. During the analytical-scale HPLC measurements, the
applied flow rate was a constant 1 ml/min.
Structure Elucidation
The compounds’mass spectra were recorded on an Agilent 1100
LC-MS instrument (Agilent Technologies, Santa Clara, CA,
USA) coupled with Thermo Q-Exactive Plus orbitrap analyzer
(Thermo Fisher Scientific, Waltham, MA, USA) used in
positive mode.
1H (800 and 500 MHz) and 13C (200 and 125 MHz) NMR
spectra were recorded at room temperature on Bruker Avance III
spectrometers equipped with cryo probeheads. Amounts of
approximately 3–5 mg of compounds were dissolved in 0.6 ml
of chloroform-d and transferred to 5 mm NMR sample tubes.
Chemical shifts are given on the d-scale and are referenced to the
solvent chloroform-d: dC = 77.00 and dH = 7.27 ppm). Pulse
programs of all experiments (1H, 13C, DEPTQ, 1D sel-TOCSY,
gs-HSQC, and gs-HMBC (optimized for 8 and 10 Hz
respectively), band–selective–HSQC, –HMBC and HSQC–
TOCSY were taken from the Bruker software library. For 1D
measurements, 64K data points were used to yield the FID. For
2D measurements, on the 500 MHz spectrometer in case of the
HSQC spectrum data points (t2 x t1) were acquired with 2 K x
128, in case of the HMBC spectrum data points (t2 x t1) were
acquired with 2 K x 256, respectively. In the band-selective
HMBC experiment, the used digital resolution was 1.04 Hz per
point; in the band-selective HSQC experiment it was 0.13 Hz per
point. For F1 linear prediction was applied to enhance the
resolution. Most 1H assignments were accomplished using
general knowledge of chemical shift dispersion with the aid of
the proton-proton coupling pattern (1H NMR spectra). The
NMR signals of the products were assigned by comprehensive
one- and two-dimensional NMR methods using widely accepted
strategies (Duddeck et al., 1998; Pretsch et al., 2002).The
1H and 13C NMR data for the steroid moiety of compounds 6
and 7, are compiled in Table 1, whereas the signals of the R-
groups are summarized in Table 2. The characteristic NMR
and HRMS spectra of compounds 6 and 7 are presented as
supporting information.
Preparation of Self-Assembled
Ecdysteroid NPs 6NP and 7NP
A 12 mg aliquot of compound 6 or 7 was dissolved in 1.5 ml of
acetone (8 mg/ml), and under mild stirring (350 rpm), the
prepared solution was added dropwise to a double volume of
Milli-Q® (Merck KGaA, Darmstadt, Germany) ultrapure water
for 5 min at RT. The spontaneous self-assembly of the
bioconjugates occurred immediately, as a consequence of local
secondary interactions guided by the hydrophobic squalene
chains. Following this, the organic solvent was evaporated at
25°C on a rotary evaporator that afforded the corresponding aq.
nanosuspensions 6NP or 7NP in a final concentration of 4 mg/ml.September 2020 | Volume 11 | Article 552088
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Nano assemblies 6NP and 7NP were initially characterized by
transmission electron microscopy (TEM) in order to investigate
their morphology. The images were taken by a FEI Tecnai G2 20
X–Twin instrument (FEI Corporate Headquarters, Hillsboro,
OR, USA) using 200 kV accelerating voltage. The samples
were drop casted on by 200 mesh, copper supported lacey–
carbon grids. In order to further investigate the size and colloidal
stability of the self–assembled particles in liquid media, dynamic
light scattering (DLS) measurements were carried out on a
Malvern Zetasizer Nano ZS instrument (Malvern Instruments,
Malvern, UK) using disposable folded capillary cells. Particle size
distribution (PSD), average hydrodynamic diameter (Z-Average)
and polydispersity index (PdI) measurements were performedFrontiers in Pharmacology | www.frontiersin.org 4to assess particle size and dispersity, while zeta potential
measurements aimed to determine long-term colloidal stability.
Cell Lines
Two non-adherent cell lines were used, L5178 mouse T-cell
lymphoma (ECACC catalog number 87111908, U.S. FDA, Silver
Spring, MD, U.S.), and its multidrug resistant counterpart
(L5178MDR) that swas established by transfection with pHa
MDR1/A retrovirus (Pastan et al., 1988). Cells were cultured in
McCoy’s 5A media supplemented with nystatin, L-glutamine,
penicillin, streptomycin, and 10% heat-inactivated horse serum,
at 37°C and 5% CO2. The MDR cell line was selected by culturing
the infected cells with 60 ng/L colchicine (Sigma). Media, horse
serum, and antibiotics were purchased from Sigma. The human
breast cancer cell lines MDA-MB-231 and MCF7 were obtained
from ECACC (European Collection of Cell Cultures, Salisbury,
UK). Cells were grown in Minimum Essential Medium (MEM)
supplemented with 10% fetal calf serum, 1% non-essential aminoTABLE 1 | 1H and 13C chemical shifts, multiplicities and characteristic coupling
constants (Hz) of the steroid moiety of compounds 6 and 7 in CDCl3.
Atom no. 6b 7a
H J (Hz) C H J (Hz) C
1b 1.20 dd 13.9; 10.7 39.85 1.21 dd 13.9; 10.9 39.88
1a 1.83 dd 13.9; 6.1 1.83 dd 13.9; 6.1
2 4.42 ddd 10.7; 6.1; 4.5 72.31 4.44 ddd 10.9; 6.1; 4.5 72.26
3 4.31 dd 4.5; 4.5 71.51 4.31 ddd 4.5; 4.5; 1.5 71.48
4b 2.16 m 27.11 2.15 m 27.07
4a 1.80 m 1.78 ddd 17.5; 13.4; 4.5
5 2.33 m 52.06 2.35 m 52.07
6 – 202.26 – 201.90
7 5.89 d 2.9 122.73 5.89 dd 2.9; 1.0 123.22
8 – 159.52 – 158.22
9 3.13 dd 9.1; 2.9 38.52 3.18 dd 9.1; 2.9 38.59
10 – 38.57 – 38.63
11b 5.31 ddd 10.4; 9.1; 6.5 70.61 5.30 ddd 10.4; 9.1; 6.5 70.21
11a – –
12b 2.01 m 37.18 2.29 m 36.11
12a 2.31 m 2.25 m
13 – 46.88 – 46.95
14 – 84.42 – 84.20
15b 2.08 m 31.84 2.10 m 32.15
15a 1.55 m 1.65 m
16b 2.08 m 21.11 2.33 m 21.10
16a 1.87 m 1.93 m
17 2.24 dd 10.0; 7.9 48.84 3.29 dd 9.7; 7.9 58.18
18 0.85 s 17.66 0.68 s 17.60
19 1.03 s 23.53 1.03 s 23.55
20 – 83.77 – 208.39
21 1.14 s 21.83 2.15 s 31.44
22 3.59 dd 9.2; 2.5 81.58
23 1.45/1.35 m 26.78
24 1.48/1.19 m 36.39
25 1.56 m 28.26
26 0.90 d 6.6 22.46
27 0.91 d 6.6 22.58
2,3-acetonide:
Meb 1.47 s 28.54 1.47 s 28.54
Mea 1.34 s 26.57 1.34 s 26.57
C – 108.21 – 108.28
20,22-acetonide:
Meb 1.32 s 26.85 – –
Mea 1.41 s 28.94 – –
C – 106.85 – –a 800/200 MHz; b 500/125 MHz; s=singlet; d=doublet; unresolved multiplet.TABLE 2 | 1H and 13C chemical shifts of the R group in compounds 6 and 7 in CDCl3.
Atom no. 7b 6b
H C H C
1′ – 172.83 – 172.82
2′ 2.36 34.66 2.33 34.69
3′ 1.66 24.64 1.64 24.62
4′ 1.34 29.03 1.38-1.29 29.03*
5′ 1.36-1.31 29.07* 29.08*
6′ 29.08* 29.08*
7′ 1.33 29.10 29.10*
8′ 1.63 24.96 1.62 24.95
9′ 2.30 34.34 2.29 34.33
10′ – 173.92 – 173.91
11′ – – – –
12′ 4.04 64.02 4.04 64.01
13′ 1.72 26.90 1.73 26.87
14′ 2.03 35.79 2.03 35.77
15′ – 133.67 – 133.67
16′ 5.13 125.06 5.14 125.03
17′ 2.08 26.65 2.07 26.64
18′ 1.99 39.66 1.99 39.66
19′ – 135.11 – 135.10
20′ 5.15 124.37 5.15 124.35
21′ 2.02 28.25* 2.02 28.24*
22′ 2.02 28.26* 2.02 28.25*
23′ 5.16 124.27 5.15 124.25
24′ – 134.96 – 134.96
25′ 1.99 39.74 1.99 39.73
26′ 2.08 26.65 2.08 26.64
27′ 5.12 124.25 5.12 124.23
28′ – 134.90 – 134.89
29′ 1.99 39.72 1.99 39.71
30′ 2.07 26.76 2.07 26.74
31′ 5.10 124.39 5.10 124.37
32′ – 131.24 – 131.25
33′ 1.69 25.68 1.69 25.69
34′ 1.60 17.67 1.61 17.66
35′ 1.60 15.99 1.61 15.99
36′ 1.60 16.04 1.61 16.03
37′ 1.60 16.03 1.61 16.02
38′ 1.60 15.86 1.61 15.86September 2020 | Volume 11 | Articlea800/200 MHz; b500/25 MHz; *tentative assignments.552088
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supplements for these experiments were obtained from Lonza
Group Ltd. (Basel, Switzerland). The cells were maintained at
37°C in humidified atmosphere containing 5% CO2.
Evaluation of the ABCB1 Inhibitory Activity
of Compounds 3 and 4
ABCB1 inhibitory activity of compounds 3 and 4 was evaluated
through the intracellular accumulation of rhodamine 123, an
ABCB1 substrate fluorescent dye, by flow cytometry as published
before (Martins et al., 2012). Briefly, 2 x 106 cells/ml were treated
with 2 or 20 µM of either compound. After 10 min incubation,
rhodamine 123 (Sigma-Aldrich) was added to a final
concentration of 5.2 mM and the samples were incubated for
20 min at 37°C in water bath. Samples were centrifuged (Heraeus
Labofuge 400, Thermo Fisher Scientific, Waltham, MA, USA)
(2000 rpm, 2 min) and washed twice with phosphate buffer
saline (PBS, Sigma-Aldrich). The final samples were re-
suspended in 0.5 ml PBS and its fluorescence measured with a
Partec CyFlow flow cytometer (Partec, Münster, Germany). 100
nM of tariquidar, kindly provided by Milica Pesǐć (Institute for
Biological Research Sinisa Stankovic, Belgrade, Serbia), was used
as a positive control.
Evaluation of the Interaction Between
Compound 3 or 4 and Doxorubicin or
Paclitaxel
The checkerboard microplate method was used to evaluate the
combined activity of doxorubicin (Teva, Budapest, Hungary) or
paclitaxel (Teva, Budapest, Hungary) and compound 3 and 4 on
the cell viability of L5178MDR, L5178, MCF-7, and MDA-MB-
231 cell lines as described before (Martins et al., 2012).
L5178MDR and L5178cells were incubated at 6,000 cells/well
density in presence of doxorubicin and/or compound 3 or 4 in
McCoy’s 5A medium (Sigma-Aldrich) for 72 h at 37°C, 5% CO2.
Then, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT, Sigma-Aldrich) was added to each well at a
final concentration of 0.5 mg/ml, and after 4 h of incubation,
100 ml of 10% sodium dodecyl sulfate (SDS) (Sigma-Aldrich) in
0.01M HCl was added to each well. The plates were further
incubated overnight, and the optical densities were read at 540
and 630 nm using an ELISA reader (Multiskan EX, Thermo
Labsystem, Milford, MA, USA). Ecdysteroids and doxorubicin
were administered at the 3.125–100 µM, and 67.35 nM–8.62 µM
concentration ranges respectively.
Regarding MCF-7 and MDA-MB-231, cells were seeded at 5 x
103 cells/well and incubated overnight for proper cell adhesion.
Afterwards, the cells were treated with the tested compounds
for 72 h at 37°C, and 5% CO2. Ecdysteroids were administered at
the same concentration range as indicated above, and the
concentration ranges for doxorubicin (Dox) and paclitaxel
(PCT) were as follows: Dox: 3.9–500 nM (MCF-7), and
7.8 nM–1.0 µM (MDA-MB-231); PCT: 0.54 pM–7.0 nM
(MCF-7), and 0.23–30 nM (MDA-MB-231). Following the
incubation, 44 µl/well MTT reagent (5 mg/ml in PBS) was
added to the samples, and after 4 h of further incubation, theFrontiers in Pharmacology | www.frontiersin.org 5supernatant was replaced with DMSO (100 µl/well) and the
plates were shaken for 45 min at 37°C to dissolve formazan
crystals. The optical density was read at 545 nm wavelength
using a microplate reader (Stat Fax-2100, Awareness Technology
INC, USA).
In all cases, the interaction was evaluated using the
CompuSyn software (CompuSyn Inc., Paramus, NJ, USA) at
each constant ratio of compound vs. doxorubicin or compound
vs. paclitaxel (M/M), and combination index (CI) values were
obtained for 50%, 75%, and 90% of growth inhibition.
Evaluation of the Interaction Between
Nanoassemblies 6NP or 7NP and Paclitaxel
on MCF-7 Cells
MCF-7 cells were cultured as described above, and the effect of
PCT on cell viability was tested by MTT assay with or without
the presence of 6NP or 7NP. Treatment groups were as follows:
serial dilutions of PCT (group 1), and serial dilutions of PCT in
the presence of a fix concentration of 10 (group 2) or 30 (group
3) µM of 6NP or 7NP. Nanoassemblies were added to the wells
directly from their aqueous solution so that they were diluted
with medium only, and no DMSO was present in any of the
wells. Dose-response curves with respect to PCT were calculated
by nonlinear regression using the log inhibitor vs. normalized
response model of GraphPad Prism 5 software.
Evaluation of the Interaction Between
Nanoassemblies 6NP or 7NP and
Doxorubicin on L5178MDR Cells
Aqueous nanosuspensions (4 mM) of 6NP or 7NP were incubated
in 6-times their volume of horse serum (Sigma-Aldrich) for 24 h
at 37°C, 5% CO2, and the resulting mixture was used as the
treatment sample. Treatment groups were as follows: serial
dilutions of Dox (group 1), and serial dilutions of Dox in the
presence of a fix concentration of 37.5 (group 2), 75 (group 3) or
150 (group 4) µM of 6NP or 7NP. Due to the amount of horse
serum added to each well in group 3, all wells including cell and
solvent controls were substituted with 22.5% of horse serum that
did not cause any observable change in the cell growth as
compared with the cell control containing 10% of horse serum
supplement. In this test, no DMSO was added to any of the wells.
Cell viability was evaluated by MTT as described above, and
dose-response curves with respect to Dox were calculated by
nonlinear regression using the log inhibitor vs. normalized
response model of GraphPad Prism 5 software.RESULTS AND DISCUSSION
Organic Synthesis
We have previously found that sidechain-cleaved ecdysteroid
acetonides may act as similarly potent adjuvant antitumor agents
as diacetonides of their parent compounds, but without any direct
inhibitory activity on the ABCB1 (also referred to as P-glycoprotein
or P-gp) efflux transporter (Hunyadi et al., 2017). To further explore
this, our work aiming to prepare 11-squalenoylated ecdysteroidsSeptember 2020 | Volume 11 | Article 552088
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hydroxypoststerone (2) from ajugasterone C (1) by oxidative
sidechain cleavage using (diacetoxyiodo)benzene (PIDA), a
hypervalent iodine(III) reagent that we previously reported to
be efficient and selective for this transformation (Issaadi et al.,
2019). Compound 2 was obtained in a good yield (74.8%).
Both compounds 1 and 2 were then subjected to further
transformations as presented in Scheme 1.
Previously, we found that dioxolane substitution of ecdysteroids
on the vicinal diols, and particularly on the 2,3-diol, is prerequisite
of a potent chemo-sensitizing effect (Martins et al., 2013). Therefore,
compounds 1 and 2 were converted to their corresponding
2,3;20,22-diacetonide (3) or 2,3-acetonide (4) analog by
phosphomolybdic acid (Martins et al., 2012), which afforded us
both derivatives in relatively good yields (Scheme 1). These
compounds were of particular interest for our study due to their
presumed adjuvant antitumor properties, and due to the sterically
not hindered 11a-OH group on their structure allowing a
convenient coupling of a squalene-derived lipophilic moiety
through esterification, and therefore providing a good opportunity
for preparing their self-assembling bioconjugate prodrugs.
Since the self-assembly inducer squalene is devoid of a suitable
chemical function for the linkage of a drug, its synthetic modification
is necessary prior to the coupling (Desmaele et al., 2012). Therefore,
we prepared compound 5 following previously published strategies,
by first transforming squalene to 1,1′,2-trisnorsqualene alcohol
(Maksimenko et al., 2014). Then we conjugated the terminal
hydroxyl moiety of this alcohol with sebacic acid, serving as linker,
to yield compound 5 whose carboxylic moiety was required for the
preparation of esters (Borrelli et al., 2014).
Our preliminary small-scale reactions indicated that the
condensation of the inducer (5) with ecdysteroid substrates 3 or 4
is chemoselective for the secondary alcohol and allows the synthesis
of bioconjugates coupled through the 11a-OH of the ajugasterone CFrontiers in Pharmacology | www.frontiersin.org 6analogs. Following scale-up and chromatographic purification, the
conjugates were stored under argon atmosphere at –20°C to ensure
their chemical stability until further utilization.
NMR Investigations
Squalenoylated compounds 6 and 7 were subjected to an in-
depth study by high-resolution NMR that allowed us to achieve a
complete signal assignment. Chemical structures and 1H and 13C
NMR data for the steroid core of each compound are shown in
Figure 1 and Tables 1 and 2, respectively. NMR spectra and the
complete signal assignment including that of the ester sidechain
coupled at C-11 are presented in detail as Supplementary
Material, Figures S1–S6.
Squalenoylation is a rapidly emerging strategy to prepare
innovative novel nanoconjugates from various bioactive
compounds (Arias et al., 2011; Desmaele et al., 2012; Borrelli
et al., 2014; Maksimenko et al., 2014; Fumagalli et al., 2017a;
Fumagalli et al., 2017b; Rouquette et al., 2019), therefore our
NMR results may be applicable and useful to the description and
purity evaluation of a wide range of such compounds. For
example, in our case, the signal ratio of ca. 5 between the
olefin protons of the sidechain (overlapping signals in the
range of 5.10–5.16 ppm) and the H-7 (5.89 ppm) was a
diagnostic measure of a complete coupling.
Preparation and Characterization of Self-
Assembled NPs
Following structure elucidation, conjugates 6 and 7 were
investigated for their ability to self-assemble to NPs in an
aqueous medium. Accordingly, 4 mg/ml stock solutions of 6NP
and 7NP were prepared through nanoprecipitation in ultrapure
water. Characteristics of the NPs obtained are presented in
Figure 2.SCHEME 1 | Semi-synthesis of ajugasterone C analogs. Reaction conditions: (a) PIDA (1 equiv.), CH3OH, RT, 1 h; (b) PMA hydrate, acetone, RT, 25 min; (c) cpd. 5:
sebacic acid (1.25 equiv.), DMAP (2 equiv.), EDC·HCl (3 equiv.), RT, Ar, overnight.September 2020 | Volume 11 | Article 552088
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samples possessed rigid morphology under such experimental
conditions. Both 6NP and 7NP had fluid, droplet-like structures
(see Supplementary Material, Figure S7). The self-assembled
droplets could mostly be located at fiber junctions where they
could cover the fibers in a wetting manner. The particles
assembled from compound 6 appeared similar in size to those
of compound 7, however, as the observed structure of the
particles depended heavily on the carbon lace layout, further
investigation was necessary.
Unfortunately, our TEM architecture was not suited for cryo
imaging, therefore DLS measurements were performed in their
place to get a more accurate picture on the size and dispersity,
furthermore the colloidal stability of the nanoparticles. The
liquid media allowed the observation of these features in a way
that is more representative of in vitro characteristics. Aliquots of
the nanosuspensions were further diluted with water in order to
prepare samples for the evaluation of particle size, represented as
PSDs by scattered light intensity (Figure 2A) and particle
number (Figure 2B), furthermore for the investigation of the
values of Z-Average, PdI, and zeta potential (Figure 2C). The
Intensity and Number PSD results were in good agreement with
one-another for both samples, with slightly shifted mean values
that can be explained by the differences between the two
representations (Bhattacharjee, 2016). Based on the number
distributions, the mean primer particle diameter of 6NP was
around 200 nm, while 7NP comprised from particles of around
145 nm. The average hydrodynamic diameters of the samples
were 239.7 and 187.9 nm respectively. These results verified the
TEM–based observations, as both samples were in comparable
size distributions, although 7NP particles were somewhat smaller.
The polydispersity index of the samples was quite low (<0.15)
indicating that both samples were highly monodispersed. The
zeta absolute value of both 6NP and 7NP were well above the
theoretical threshold of ±30 mV, therefore their long-term
colloidal stability was verified. Additionally, electric repulsion
between 6NP particles appeared to be slightly larger than betweenFrontiers in Pharmacology | www.frontiersin.org 77NP particles, although 6NP particles proved larger than the
7NP ones.
The chemical/biological stability of the nanoprecipitated
particles in the presence of horse serum was also investigated by
DLS. This was to estimate the rate of compounds 6 and 7 getting
dissolved into serum lipoproteins when 6NP and 7NP are placed into
a lipoprotein-rich medium, so that we can conduct our in vitro
bioactivity studies on these nanoassemblies in conditions closer to
the situation in vivo (see section Interactions of Nanoassemblies 6NP
and 7NP With Chemotherapeutics). To this, a 72-h longitudinal
study was performed, throughout which the nanoparticle samples
were incubated in horse serum (cell culture supplement in the
subsequent in vitro studies on L5178MDR cells) with 1:6 volume
ratios. At the 0-, 24-, 48-, and 72-h marks, small aliquots were
collected from the incubating mixtures and DLS measurements
were performed on appropriately diluted (150 ppm for
nanoparticles) aqueous dispersions.
Both 6NP and 7NP demonstrated similar behavior according
to the results provided by the stability measurements. Figure 3A
shows the average hydrodynamic diameter of the as–prepared
samples, and their size decrease as the function of time due to the
presence of horse serum. The Z–average of 6NP particles
decreased from 240 nm to 166 nm which is roughly a 31%
decrease in radius, while 7NP went down from 188 nm to 152 nm,
resulting in a 19% radius decrease. The decomposition of the
self–assembled particles happened during the first day of the
experiments, after which the particle diameters stabilized, most
likely due to the depletion of available macromolecules in
the system, which could facilitate particle decomposition. The
changes in zeta potential values in Figure 3B supported the
pervious results. The horizontal lines in the graphs represent
the zeta potentials of clean horse medium and the original
nanoparticles respectively. While the results did not vary
substantially throughout the experiments, a change from 0 to
24 h can be observed in both cases here as well. The initial values
corresponding to the 0 h experiments were quite close to the zeta
potential of the serum, while the later experiments yieldedFIGURE 1 | Chemical structures of compounds 6 and 7 and their atomic numbering.September 2020 | Volume 11 | Article 552088
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within the system.
While hydrodynamic diameter should not be confused with
primer article diameter, some assumptions could be made
regarding the release of compounds 6 and 7 from their
corresponding nanoassemblies. Due to the relatively low
standard deviation of the sample sizes, it can be speculated
that the decrease in hydrodynamic diameter is proportional to
the decrease of primer particle size as well, therefore the radius
decreases of 31% and 19% for 6NP and 7NP respectively could be
translated into mass, using the expressions of sphere volume
(Equation 1) and density (Equation 2). Approximating the self–
assembled nanoparticles as ideal spheres with uniform density,
and substituting the volume expression into the equation of
density (Equation 3), particle radius is directly proportional to




3 (1) r = mV  (2)
m = 43 pr










After converting the numbers, 6NP is predicted to release
around 68% of its compound 6 contents, while 7NP potentially
releases 58% of compound 7 from the self–assembled
nanostructures due to the presence of horse serum. Naturally,
these numbers are loose estimates at best, however, they could
serve as indicators regarding the biological activity of the
prepared nanoassemblies.
Interaction of Compounds 3 and 4 With
Chemotherapeutics
Compounds 3 and 4, parent compounds to 6 and 7, respectively,
were tested on the chemoresistance of five cancer cell lines
including a susceptible/resistant cell line pair modeling ABCB1
efflux-mediated multi-drug resistance.
First, efflux pump inhibitory activity of the compounds was
assessed. To this, multi-drug resistant L5134MDR mouse
lymphoma cells were used, that are transfected to express the
human ABCB1 transporter (Pastan et al., 1988). The rhodamine
123 accumulation assay indicated a weak efflux inhibition by
compound 3 (inactive at 2 µM, 27.4 ± 1.9% inhibition at 20µM),
while compound 4 was inactive (<5% inhibition) at up to 20 µM.A
B
C
FIGURE 2 | Intensity (A) and Number (B) particle size distribution graphs, and average hydrodynamic diameter, polydispersity index, and zeta potential values (C) of
6NP (left) and 7NP (right).September 2020 | Volume 11 | Article 552088
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ecdysteroid 2,3;20,22-diacetonides and their sidechain cleaved
analogs, namely that removal of the sidechain eliminates efflux
pump inhibitory activity (Hunyadi et al., 2017).
Subsequently, the compounds were evaluated on L5134MDR
cells for their interaction with doxorubicin, and on MCF-7 and
MDA-MB-231 breast cancer cells for their interaction with
doxorubicin and paclitaxel. The checkerboard microplate
method was used, and the results were evaluated by the Chou-
Talalay method (Chou, 2006) as shown in Table 3.
As we expected based on our previous results (Martins et al.,
2012), compound 3 exerted strong synergism with doxorubicin on
the MDR mouse lymphoma cell line. Somewhat surprisingly,
however, compound 3 did not show synergism with doxorubicin
on MCF-7 or MDA-MB-231 cells, and it even moderately
antagonized the effect of paclitaxel on both breast cancer cell
lines. Previously we found that 20-hydroxyecdysone 2,3;20,22-
diacetonide (20DA) could decrease cytotoxicity of cisplatin on
MCF-7 cells but increased the effect of paclitaxel on the same cell
line. This suggests that the additional 11a-OH group and/or the
missing 25-OH group (compound 4 vs. 20DA) plays a more
important and complex role in the structure-activity relationships
than previously thought.
As for compound 4 combined with doxorubicin, no
synergism was found on the MDR mouse lymphoma or the
MCF-7 cells, but a moderate synergism (CIavg 0.7–0.85) was
observed on the triple-negative MDA-MB-231 cell line. Several
doxorubicin-containing neoadjuvant chemotherapeutic
strategies have shown promise in clinical studies on triple-
negative breast cancer (TNBC) (Park et al., 2018; Bergin and
Loi, 2019). While the activity of compound 4 is rather weak inFrontiers in Pharmacology | www.frontiersin.org 9this regard, mainly when comparing with that of compound 3 on
the MDR lymphoma cell line, it may still be of interest to initiate
further studies on ecdysteroid derivatives in combination with
doxorubicin on various TNBC models.
It was a most unexpected outcome of our study that compound
4 acted in strong antagonism (CIavg>3.3) with paclitaxel, in other
words, that it exerted a potent cytoprotective effect against this
chemotherapeutic agent on MCF-7 cells. While this makes this
compound and, supposedly, its pro-drugs including 7NP completely
unsuitable as an adjuvant anticancer agent, it may suggest its
possible cytoprotective effect against other stressors.
At this time, it is hard to point out the exact mechanism of
action for the above-detailed effects of compounds 3 and 4 on the
studied cancer cell lines. The interaction of compound 3 with
doxorubicin is clearly connected somehow to the upregulated
ABCB1, since it was much weaker on the L5178 cells than on
the L5178MDR cells. Further, similarly to our previous results
on ecdysteroid 2,3-acetonides, we found that a synergistic
interaction does not require that the ecdysteroid acts as a
potent efflux inhibitor. It is worth mentioning, however, that
the rhodamine123 accumulation is a rapid assay with a 20 min
incubation that was designed to assess functional inhibition of
the transporter. Therefore, it does not give any information
about what happens during the 72 h–long incubation period
on the checkerboard plates. To evaluate this, it would be
important to conduct further studies on ecdysteroid 2,3-
acetonides concerning their potential to interfere with the
expression of the pump.
Nevertheless, while the synergistic activity of ecdysteroid
acetonides at least with doxorubicin appears to be strongly
amplified by upregulated ABCB1, this interaction could also beA
B
FIGURE 3 | Stability measurements of the self–assembled nanoparticles 6NP and 7NP in horse serum as a function of time according to average hydrodynamic
diameter (A) and zeta potential (B) changes using dynamic light scattering.September 2020 | Volume 11 | Article 552088
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lymphoma, suggesting that ABCB1 overexpression is not a
prerequisite for this bioactivity. This fits well with our previous
results on other ecdysteroid derivatives that very strongly
hypersensitized the non-MDR SH-SY5Y neuroblastoma cell
line to vincristine (Müller et al., 2017). As in our previous
studies, here we also observed the trend that the strength of
interaction depends on the ecdysteroid-chemotherapeutic ratio,
and it seems to have a “best ratio” where the interaction is the
most significant. It may be of interest in this regard that we
recently found 20-hydroxyecdysone (20E; structural isomer of
compound 1, differing in the position of one hydroxyl group)
and poststerone (11-deoxy analog of compound 2) to act on
protein kinase B (Akt) with a bell-shaped dose-response curve
(Issaadi et al., 2019). Ecdysteroids can modulate AktFrontiers in Pharmacology | www.frontiersin.org 10phosphorylation in a Ca2+-dependent manner (Gorelick-
Feldman et al., 2010), and while this was first observed for 20E
as an activation, some ecdysteroids may also act as inhibitors
(Csábi et al., 2015). Considering the central role of Akt in cell
death and survival (Song et al., 2019), one may hypothesize that
it should somehow be involved in the chemoresistance altering
activity of ecdysteroids. Unfortunately, at this point we have no
information about how ecdysteroid acetonides influence
this pathway.
Interactions of Nanoassemblies 6NP and
7NP With Chemotherapeutics
To evaluate what relevance the above findings with compounds 3
and 4 may have concerning the bioactivity of their prodrug
nanoassemblies (6NP and 7NP, respectively), we focusedTABLE 3 | Interaction of compounds 3 and 4 with chemotherapeutics on cancer cell lines at 50%, 75%, and 90% of growth inhibition (ED50, ED75, and ED90, respectively).
Compounds Drug CI at
combined Cell line ratioa ED50 ED75 ED90 Dm m r CIavg
3 + Dox L5178MDR 11.6:1 0.09 0.10 0.12 0.71 1.524 0.962 0.11
23.2:1 0.10 0.13 0.15 1.31 1.470 0.968 0.14
46.4:1 0.13 0.17 0.23 2.25 1.360 0.979 0.19
3 + Dox L5178 75:1 0.40 0.51 0.67 6.97 0.809 0.847 0.57
150:1 0.88 0.63 0.44 25.27 1.438 0.916 0.58
300:1 1.22 1.17 1.11 50.82 1.024 0.946 1.15
3 + Dox MCF-7 100:1 1.26 0.82 0.60 10.5 2.468 0.942 0.78
200:1 1.12 1.06 1.16 15.6 1.545 0.995 1.12
400:1 1.21 1.06 1.07 25.3 2.146 0.998 1.09
3 + PCT MCF-7 7,143:1 1.21 1.34 1.59 16.5 1.545 0.967 1.44
14,285:1 1.27 1.22 1.25 26.5 2.284 0.999 1.24
28,571:1 1.10 1.00 0.96 31.3 3.206 0.992 1.00
3 + Dox MDA-MB-
231
100:1 1.43 1.01 1.01 12.8 1.534 0.940 1.08
200:1 1.09 0.78 0.78 16.9 2.062 0.948 0.83
400:1 1.10 0.87 0.93 26.5 2.506 0.910 0.94
3 + PCT MDA-MB-
231
1,667:1 1.71 1.15 1.48 17.4 1.265 0.990 1.41
3,333:1 1.48 1.40 2.28 24.9 1.180 0.988 1.85
6,667:1 1.31 1.48 2.48 32.9 1.295 0.987 1.95
4 + Dox L5178MDR 11.6:1 1.20 0.93 0.72 6.64 1.727 0.991 0.87
23.2:1 1.09 0.88 0.72 10.9 1.688 0.995 0.83
46.4:1 1.17 0.93 0.75 19.74 1.822 0.996 0.88
4 + Dox L5178 75:1 1.80 1.97 2.17 20.97 2.159 0.964 2.04
150:1 2.12 2.41 2.80 44.87 1.895 0.977 2.56
300:1 1.69 2.52 3.84 60.94 1.239 0.923 3.04
4 + Dox MCF-7 100:1 1.41 1.45 1.51 9.40 1.426 0.976 1.47
200:1 1.28 1.07 0.89 16.8 1.958 0.966 1.02
400:1 1.48 1.67 1.91 37.0 1.246 0.995 1.76
4 + PCT MCF-7 7,143:1 2.78 3.08 3.41 21.2 1.608 0.972 3.19
14,285:1 2.92 3.25 3.61 43.2 1.591 0.954 3.37
28,571:1 2.38 3.08 3.98 66.9 1.303 0.998 3.41
4 + Dox MDA-MB-
231
100:1 0.58 0.62 0.78 7.9 1.004 0.996 0.69
200:1 0.64 0.69 0.92 15.8 1.101 0.992 0.80
400:1 0.66 0.71 0.94 27.1 1.302 0.976 0.81
4 + PCT MDA-MB-
231
1,667:1 1.74 1.52 1.33 4.730 1.514 0.997 1.46
3,333:1 1.58 1.10 0.77 8.536 2.165 1.000 1.02
6,667:1 1.25 1.29 1.34 13.326 1.214 0.973 1.31September 2020 | Volume 11 | Article 55CI, combination index; CIavg, weighted average CI value; CIavg = (CI50 + 2CI75 + 3CI90)/6. CI < 1, CI = 1, and CI > 1 represent synergism, additivity, and antagonism, respectively. Dm, m,
and r represent antilog of the x-intercept, slope, and linear correlation coefficient of the median-effect plot, respectively. Dox, doxorubicin; PCT, paclitaxel. Strongest interactions observed
are highlighted as red (synergism) or blue (antagonism).
aDrug ratios represent molar ratios in each case.2088
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mentioned above. Therefore, we tested 6NP and 7NP in
combination with PCT on MCF-7 cells, and in combination
with doxorubicin on the L5178MDR cells. First, we tested the
chemoresistance modulating activity of 6NP and 7NP by simply
adding their aqueous nanosuspensions to the cells. Since neither
nanosuspension exerted measurable cytotoxicity on MCF-7 cells,
the checkerboard setup could not be used in this case, therefore
we selected two fix concentrations (10 and 30 µM) of 6NP and
7NP for testing their effect on the cytotoxicity of paclitaxel; the
results are shown in Figure 4A. Concerning the MDR mouse
lymphoma, cytotoxicity for 6NP was very low but measurable,
therefore we first tested it by the checkerboard setup. To our
surprise, the interaction with doxorubicin measured this way
gave CIavg values in the range of 1.24–1.51 that represents
moderate or even stronger antagonism instead of the expected
synergism. Considering that this experimental setup might be
rather different from the in vivo situation where the
nanoparticles should get dissolved into serum lipoproteins as
individual pro-drug molecules, we then tried to re-evaluate the
combination treatment in a possibly more relevant new
experiment. To this, horse serum (that is the supplement used
for the mouse lymphoma cells) was first added to the
nanoparticles in a 6:1 ratio, the mixture was incubated for 24 h
(that was the plateau of the decrease in NP size, see section
Preparation and Characterization of Self-Assembled NPs), and
this was then further tested on the doxorubicin resistance of
L5178MDR cells. Again, the checkerboard setup was ruled out due
to the non-measurable cytotoxicity of the horse serum-
pretreated 6NP and 7NP, therefore fix concentrations of these
were tested; results are shown in Figure 4B.
It is clear from our results that both 6NP and 7NP, similarly to
their corresponding parent compounds 3 and 4, significantly
protected the MCF-7 cells from the cytotoxic effect of paclitaxel.Frontiers in Pharmacology | www.frontiersin.org 11Further, the relative potency of the two nanoassemblies seems to
correlate with that of compounds 3 and 4 (i.e. 4 > 3 and
7NP > 6NP), which would support the assumption that the
nanoparticles indeed worked as prodrugs of the 11a-
hydroxylated parent ecdysteroids 3 and 4. On the MDR mouse
lymphoma cell line, however, a surprising opposite effect was
observed for 3 and 6NP: in contrast with the strong synergism
between compound 3 and doxorubicin, 6NP significantly
decreased the efficacy of the Dox, regardless of the fact that a
large fraction of 6NP were pre-dissolved in horse serum to
liberate compound 6 in its free form (see Figure 3 and eq. 5
and 6). Therefore, this nanoassembly cannot deliver compound 3
into L5178MDR cells as a prodrug. A very likely explanation to
this is connected to the endocytosis of lipoproteins (Zanoni et al.,
2018) in which the squalenoylated prodrug is dissolved. Because
of this, the prodrug ends up in the acidic (pH ca. 4.5)
environment of lysosomes (Hu et al., 2015). This may already
be enough to cleave the acid sensitive 2,3-acetonide group
(Martins et al., 2012) that is of major importance to a strong
chemosensitizing effect of ecdysteroids (Martins et al., 2013).
Therefore, it appears that instead of the adjuvant antitumor
ecdysteroid diacetonide 3, the 20,22-monoacetonide, or, to some
extent, even the parent compound ajugasterone C (1) gets
eventually released from compound 6 after treatment by 6NP.
Similarly, this should also be happening with 7NP that, after
internalization, likely releases compound 2 instead of 4. It is not
without precedence that an ecdysteroid and its diacetonide
derivative act in an opposite way on the chemoresistance of
tumor cells: we previously found 20-hydroxyecdysone (20E) to
act in antagonism with doxorubicin on L5178MDR cells, in
contrast with the strong synergism observed for 20E 2,3;20,22-
diacetonide (Martins et al., 2012).
The above findings have two major implications. First, the
strategy of using squalenoylated ecdysteroid nanoparticles asA B
FIGURE 4 | Interaction of 6NP and 7NP with paclitaxel on MCF-7 (A) and with doxorubicin on L5178MDR cells (B). The bars show the IC50 values of the
chemotherapeutic agent with or without the presence of a given fix concentration of 6NP or 7NP, error bars show SEM. For the results shown in (B), the
nanosuspensions were preincubated with 6x volume of horse serum for 24 h. * and **: p < 0.05, and p < 0.01, respectively, by one-way ANOVA followed by
Dunnett’s post-hoc test as compared with the single treatment; *(B) and **(B): p < 0.05, and p < 0.01, respectively, by one-way ANOVA followed by planned
comparisons with the single treatment or with the specified other combination by Bonferroni’s post-hoc test.September 2020 | Volume 11 | Article 552088
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the 2,3-acetonide moiety with an acid-resistant alternative. Our
current results also suggest that our previous success in using this
strategy (Fumagalli et al., 2018) may have been connected to the
release of 20E 20,22-monoacetonide that is less potent than the
diacetonide but still active in decreasing tumor resistance
(Martins et al., 2012). If it is indeed the case, that would mean
that with an appropriate acid-resistant 2,3-substituent the
previously observed antitumor action could be further improved.
Second, while the cytoprotective nature of the herein reported
squalenoylated ecdysteroid acetonide nanoparticles makes them
certainly not useful against cancer, it points towards a possible new
strategy to deliver adaptogen ecdysteroids to target tissues with an
aim to increase stress resistance. Above cancer, LDL-R is
upregulated in some healthy tissues and organs; a most obvious
example for this is the liver (van de Sluis et al., 2017) but LDL-R
also plays an important role in the blood-brain barrier (BBB)
(Dehouck et al., 1994) and can be exploited for facilitating
transport across the BBB (Molino et al., 2017). As such, squalene
conjugation offers a means of targeting in many problematic
pathologies other than cancer. Therefore, the observed activity of
compounds 4, 6NP, and 7NP suggests further studies on relevant,
preferably in vivo pharmacological models to critically evaluate any
possible therapeutic potential of the current findings.CONCLUSIONS
In this work, two new squalenoylated ecdysteroid pro-drugs were
prepared, fully characterized, and formulated to self-assembling
nanoparticles. In both cases, the successful submicron assembly of
compounds 6 (derived from compound 3) and 7 (from compound
4) was achieved into 6NP and 7NP respectively. Both 6NP and 7NP
formed monodispersed and stable suspensions consisting of fluid,
droplet–like particles in a similar size range. Based on DLS results,
6NP is expected to possess slightly greater colloidal stability,
although the in vivo behavior of the compounds might vary
substantially and requires further investigation. The employed
functionalization of the ecdysteroids 3 and 4 allows their targeting
to tissues containing high levels of LDL-receptor. Compound 3
strongly potentiated the antitumor action of doxorubicin on an
MDR lymphoma cell line, while compound 4 was a potent
cytoprotective agent strongly antagonizing the effect of paclitaxel
on MCF–7 cells. Surprisingly, however, both nanoassemblies 6NP
and 7NP antagonized the chemotherapeutic agents’ effect on the
studied cancer cell lines. This happens most likely due to the effect
of lysosomes resulting in the acid-catalyzed release of the 20,22-
monoacetonide and/or the non-substituted form of compound 1
and compound 2 from 6NP and 7NP, respectively. We may
conclude that i) exploiting the adjuvant antitumor action of
squalenoylated ecdysteroid nanoassemblies requires the design
and synthesis of appropriate acid-resistant 2,3-substituents
instead of the acetonide group, and ii) the herein reported
nanoparticles have no antitumor potential but they might be
promising cytoprotective agents targeting LDL-R upregulated
tissues such as for example the liver or the blood-brain barrier.Frontiers in Pharmacology | www.frontiersin.org 12DATA AVAILABILITY STATEMENT
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Duddeck, H., Dietrich, W., and Tóth, G. (1998). Structure Elucidation by Modern
NMR. (Steinkopff, Heidelberg). doi: 10.1007/978-3-642-88310-1
Fumagalli, G., Marucci, C., Christodoulou, M. S., Stella, B., Dosio, F., and
Passarella, D. (2016). Self-assembly drug conjugates for anticancer treatment.
Drug Discov. Today 21, 1321–1329. doi: 10.1016/j.drudis.2016.06.018
Fumagalli, G., Stella, B., Pastushenko, I., Ricci, F., Christodoulou, M. S., Damia, G.,
et al. (2017a). Heteronanoparticles by self-Assembly of Doxorubicin and
Cyclopamine Conjugates. ACS Med. Chem. Lett. 8, 953–957. doi: 10.1021/
acsmedchemlett.7b00262
Fumagalli, G., Christodoulou, M. S., Riva, B., Revuelta, I., Marucci, C., Collico, V.,
et al. (2017b). Self-assembled 4-(1,2-diphenylbut-1-en-1-yl)aniline based
nanoparticles: podophyllotoxin and aloin as building blocks. Org. Biomol.
Chem. 15, 1106–1109. doi: 10.1039/C6OB02591A
Fumagalli, G., Giorgi, G., Vagvolgyi, M., Colombo, E., Christodoulou, M. S.,
Collico, V., et al. (2018). Heteronanoparticles by Self-Assembly of Ecdysteroid
and Doxorubicin Conjugates to Overcome Cancer Resistance. ACS Med.
Chem. Lett. 9, 468–471. doi: 10.1021/acsmedchemlett.8b00078
Gorelick-Feldman, J., Cohick, W., and Raskin, I. (2010). Ecdysteroids elicit a rapid
Ca2+ flux leading to Akt activation and increased protein synthesis in skeletal
muscle cells. Steroids 75, 632–637. doi: 10.1016/j.steroids.2010.03.008
Hu, Y.-B., Dammer, E. B., Ren, R.-J., and Wang, G. (2015). The endosomal-
lysosomal system: from acidification and cargo sorting to neurodegeneration.
Transl. Neurodegener. 4, 18–18. doi: 10.1186/s40035-015-0041-1Frontiers in Pharmacology | www.frontiersin.org 13Hunyadi, A., Gergely, A., Simon, A., Toth, G., Veress, G., and Bathori, M. (2007).
Preparative-scale chromatography of ecdysteroids of Serratula wolffli andrae. J.
Chromatogr. Sci. 45, 76–86. doi: 10.1093/chromsci/45.2.76
Hunyadi, A., Csabi, J., Martins, A., Molnar, J., Balazs, A., and Toth, G. (2017).
Backstabbing P-gp: Side-Chain Cleaved Ecdysteroid 2,3-Dioxolanes Hyper-
Sensitize MDR Cancer Cells to Doxorubicin without Efflux Inhibition.
Molecules 22, 199. doi: 10.3390/molecules22020199
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